What Is a Liquid Biopsy and How Does It Work?

A liquid biopsy is a test performed on a bodily fluid, most commonly blood, to detect signs of cancer. This non-invasive procedure uses a simple blood draw to find cancer cells or small pieces of DNA from tumor cells circulating in the bloodstream. The information gathered helps doctors understand the genetic makeup of a tumor, which can guide medical decisions.

The Science Behind the Test

A liquid biopsy identifies biomarkers that tumors release into the bloodstream, primarily circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). CTCs are intact tumor cells that have broken away from the primary tumor and entered the circulation. These cells can be analyzed to provide insights into the cancer’s characteristics.

The test also detects ctDNA, which are small fragments of genetic material shed by dying cancer cells. This ctDNA carries the same genetic mutations as the original tumor, acting as a genetic trail. By sequencing this DNA, scientists can create a detailed profile of the mutations driving the cancer’s growth.

The process begins with a standard blood draw, from which plasma is separated. Sensitive laboratory techniques are then used to isolate and analyze the CTCs or ctDNA present in the sample. This analysis reveals specific genetic or molecular changes within the tumor, which informs its use in cancer management.

Applications in Cancer Care

A primary use of liquid biopsies is guiding treatment selection. The genetic information from ctDNA can reveal specific mutations within a tumor. For example, detecting an EGFR gene mutation in non-small cell lung cancer can indicate that a targeted therapy designed to attack that specific mutation is likely to be effective. This allows for a more personalized approach to treatment.

Liquid biopsies are also used to monitor treatment effectiveness. By taking multiple samples over time, doctors can track the amount of ctDNA in the blood. A decrease in ctDNA levels can suggest the treatment is effective, while a rise may indicate the cancer is growing or has developed resistance to the therapy, allowing for timely adjustments.

Another application is detecting cancer recurrence. After treatment, liquid biopsies can monitor for the return of cancer, sometimes months before it would be visible on imaging scans. This early detection provides an opportunity to intervene sooner. Research is also ongoing into using these tests for early cancer screening in high-risk populations, though this is not yet standard practice.

Comparison with Traditional Tissue Biopsy

A primary difference between liquid and tissue biopsies is the level of invasiveness. A liquid biopsy requires only a simple blood draw, making it far less invasive than a traditional tissue biopsy, which involves surgery or a needle to remove tumor tissue. This makes liquid biopsies easier for patients to tolerate and allows for repeated testing.

The type of information each test provides also differs. A tissue biopsy gives a direct physical sample of the tumor, allowing for examination of its structure, or grade, under a microscope. A liquid biopsy provides a genetic snapshot of the cancer throughout the body, as it can detect DNA from both the primary tumor and any metastatic sites, capturing a broader picture of the tumor’s genetic diversity.

The choice between a liquid or tissue biopsy depends on the clinical situation. A tissue biopsy is the standard for an initial cancer diagnosis because it provides definitive proof of cancer and its type. Liquid biopsies are useful for monitoring the disease, assessing treatment response, or when a tissue biopsy is not feasible. In many cases, the two tests complement each other.

Current Limitations and Accessibility

Liquid biopsies have technical limitations, including the potential for false negatives. Not all tumors shed a detectable amount of DNA or cells into the bloodstream, so a negative result does not always rule out cancer. Interpreting the results can also be complex, as some genetic mutations found in the blood may not be clinically significant.

Accessibility is another consideration. While becoming more common, liquid biopsies are not yet a universal standard of care for all types and stages of cancer. Their use depends on the specific cancer, whether it is metastatic, and what information the clinical team is seeking. Insurance coverage can also vary, which may affect a patient’s ability to receive the test.

Cellular Screening: What It Is and How It Works

What Is an ECMO Circuit and How Does It Work?

The Newest Multifocal Intraocular Lenses Explained